Tempus completes Phase I exploration program in Ecuador

|

Published 24-FEB-2021 08:30 A.M.

|

3 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.


Click Here to View Latest Articles

Tempus Resources Limited (ASX:TMR, TSX.V: TMRR) this week announced the completion of the Phase I exploration program at its Valle de Tigre II Project located in southeastern Ecuador

The Phase I sampling program consisting of 167 soil samples, 20 stream sediment samples and 9 rock samples.

Completed by field crews, all samples have now been sent to SGS del Ecuador, in Guayaquil, where they will be prepared before being sent to SGS del Peru for analysis.

During the sampling program, Tempus geologists identified coarse gold in streams using traditional panning methods with up to 11 gold grains in one pan along with several artisanal gold workings in the sampling area.

Visible gold from stream sediment panning at Valle del Tigre.

Rock samples proximal to these gold workings contained sulphide veins with visible pyrite-chalcopyrite-bornite within altered sandstone and granitic rocks.

The gold mining activities at VdT appear to be along mineralised structures which are coincident with strong conductive anomalies identified in the airborne ZTEM geophysical survey.

Commenting on the assay results, Tempus CEO/President Jason Bahnsen said, “We look forward to receiving the assay results from the 198 samples in this initial program.

“The presence of both visible gold and copper mineralization during the field work is very encouraging and together with the geophysical anomalies suggest the potential for both gold and copper porphyry mineralization within the project area.

“Valle del Tigre II is situated in the heart of the Cordillera del Condor mineral belt of southeast Ecuador with the Mirador porphyry copper mine to the north and the Fruta del Norte gold project to the south.”

Valle del Tigre II Project

The Valle del Tigre II project is a grassroots-stage exploration project in the highly prospective Cordillera del Condor mineral belt of southeast Ecuador.

The Valle del Tigre II boundary is situated approximately 2.5 km northwest of Lundin Mining’s, Fruta del Norte, epithermal Au-Ag deposit (7.35 M oz Au @ 9.61 g/t Indicated Resource) and approximately 15 km southwest of the Mirador Cu-Au porphyry deposit (3.2 Mt Cu, 3.4 Moz Au, and 27.1 Moz Ag in proven and probable reserves) owned by CRCC-Tongguan Investment Co., as shown below.

Valle del Tigre II & Rio Zarza Locations.

The property is underlain by the same sedimentary and volcanic rock sequence and lies within the same structural corridor as Fruta del Norte (FdN).

2021 Exploration

Due to the impact of COVID-19 global pandemic over the past year, the Ecuadorian Presidential elections and the recent exploration results, Tempus has placed previous strategic discussions regarding the Rio Zarza project on hold for the present time.

Tempus is currently not planning to complete any drilling on the Rio Zarza Project during the 2021 year.

The Tempus exploration activities in Ecuador during 2021 will focus on the identification and development of drill targets at Valle del Tigre II to complement the drill ready Rio Zarza project.

The company is encouraged by the potential of its Valle Del Tigre II and Rio Zarza exploration projects in Ecuador and believe these projects will generate significant value for Tempus shareholders.



General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.

 

Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free

X